BiotechTube

nemolizumab (CIM331)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

Nov 1, 2013 → Jun 1, 2016

NCT ID
NCT01986933

About nemolizumab (CIM331)

nemolizumab (CIM331) is a phase 2 stage product being developed by Chugai Pharmaceutical for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01986933. Target conditions include Atopic Dermatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01986933Phase 2Completed

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaApproved
85

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77